Business Description
OptimizeRx Corp
NAICS : 621610
SIC : 8099
ISIN : US68401U2042
Total Employee Number:
105Description
OptimizeRx Corp is engaged in the healthcare market in the United States. is a digital healthcare technology company that connects over two million HCPs and millions of their patients through an intelligent technology platform embedded within a proprietary omnichannel network. OptimizeRx helps life sciences organizations engage and support their customers through its combined HCP and DTC marketing strategies.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 0.85 | |||||
Equity-to-Asset | 0.78 | |||||
Debt-to-Equity | 0.18 | |||||
Debt-to-EBITDA | 1.25 | |||||
Interest Coverage | 2.83 | |||||
Piotroski F-Score | 8/9 | |||||
Altman Z-Score | 2.21 | |||||
Beneish M-Score | -2.6 | |||||
WACC vs ROIC | ||||||
Growth Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 17.9 | |||||
3-Year EPS without NRI Growth Rate | 44.2 | |||||
3-Year FCF Growth Rate | 19 | |||||
3-Year Book Growth Rate | -2.5 |
Momentum Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 73.72 | |||||
9-Day RSI | 61.88 | |||||
14-Day RSI | 54.87 | |||||
3-1 Month Momentum % | -17.36 | |||||
6-1 Month Momentum % | -57.67 | |||||
12-1 Month Momentum % | -61.56 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 5.37 | |||||
Quick Ratio | 5.37 | |||||
Cash Ratio | 1.93 | |||||
Days Sales Outstanding | 114.38 | |||||
Days Payable | 27.47 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -3.2 | |||||
Shareholder Yield % | 7.47 |
Profitability Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 70.04 | |||||
Operating Margin % | 13.58 | |||||
Net Margin % | 6.37 | |||||
EBITDA Margin % | 17.74 | |||||
FCF Margin % | 13.33 | |||||
OCF Margin % | 13.4 | |||||
ROE % | 5.55 | |||||
ROA % | 4.01 | |||||
ROIC % | 7.58 | |||||
3-Year ROIIC % | 24.98 | |||||
ROC (Joel Greenblatt) % | 65.34 | |||||
ROCE % | 9.67 | |||||
Years of Profitability over Past 10-Year | 3 | |||||
Moat Score | 3 | |||||
Tariff Resilience Score | 7 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 16.34 | |||||
Forward PE Ratio | 6.1 | |||||
PE Ratio without NRI | 5.25 | |||||
Price-to-Owner-Earnings | 21.1 | |||||
PS Ratio | 1.03 | |||||
PB Ratio | 0.83 | |||||
Price-to-Tangible-Book | 5.66 | |||||
Price-to-Free-Cash-Flow | 7.59 | |||||
Price-to-Operating-Cash-Flow | 7.55 | |||||
EV-to-EBIT | 7.52 | |||||
EV-to-EBITDA | 5.82 | |||||
EV-to-Revenue | 1.03 | |||||
EV-to-Forward-Revenue | 1.07 | |||||
EV-to-FCF | 7.75 | |||||
Price-to-GF-Value | 0.44 | |||||
Price-to-Projected-FCF | 0.75 | |||||
Price-to-Median-PS-Value | 0.24 | |||||
Price-to-Graham-Number | 1.15 | |||||
| Price-to-Net-Current-Asset-Value | 5.78 | |||||
Earnings Yield (Greenblatt) % | 13.3 | |||||
FCF Yield % | 13.33 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:OPRX
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
OptimizeRx Corp Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 107.345 | ||
| EPS (TTM) ($) | 0.35 | ||
| Beta | 1.2778 | ||
| 3-Year Sharpe Ratio | -0.1 | ||
| 3-Year Sortino Ratio | -0.16 | ||
| Volatility % | 70.41 | ||
| 14-Day RSI | 54.87 | ||
| 14-Day ATR ($) | 0.3393 | ||
| 20-Day SMA ($) | 5.0935 | ||
| 12-1 Month Momentum % | -61.56 | ||
| 52-Week Range ($) | 4.54 - 22.25 | ||
| Shares Outstanding (Mil) | 18.77 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 8 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
OptimizeRx Corp Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
OptimizeRx Corp Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings conference call for 2026 | 2026-11-06 16:30 | In 129 days | ||
| Third quarter earnings results for 2026 | 2026-11-06 | In 128 days | ||
| Second quarter earnings conference call for 2026 | 2026-08-07 16:30 | In 38 days | ||
| Second quarter earnings results for 2026 | 2026-08-07 | In 37 days | ||
| General meeting for 2026 | 2026-06-09 10:00 | 5.05 (-1.94%) | ||
| First quarter earnings conference call for 2026 | 2026-05-12 16:30 | 6.21 (-2.36%) | ||
| First quarter earnings results for 2026 | 2026-05-12 | 6.21 (-2.36%) | ||
| Annual report for 2025 | 2026-03-12 | 6.67 (+1.68%) | ||
| Fourth quarter earnings conference call for 2025 | 2026-03-05 16:30 | 7.87 (+6.64%) | ||
| Fourth quarter earnings results for 2025 | 2026-03-05 | 7.87 (+6.64%) |
Show
Entries
OptimizeRx Corp Frequently Asked Questions
What is OptimizeRx Corp(OPRX)'s stock price today?
The current price of OPRX is $5.72. The 52 week high of OPRX is $22.25 and 52 week low is $4.54.
When is next earnings date of OptimizeRx Corp(OPRX)?
The next earnings date of OptimizeRx Corp(OPRX) is 2026-08-07 Est..
Does OptimizeRx Corp(OPRX) pay dividends? If so, how much?
OptimizeRx Corp(OPRX) does not pay dividend.
Guru Commentaries on NAS:OPRX
No articles.
Press Release
Articles on OptimizeRx Corp
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers